The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.
 
Wungki Park
Honoraria - American Physician Institute; IntegrityCE
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; EXACT Therapeutics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Break Through Cancer (Inst); Merck (Inst); Miracogen (Inst); NIH (Inst); NIH (Inst); Parker Institute for Cancer Immunotherapy (Inst); The Society of Memorial Sloan Kettering (Inst)
 
Jian Zhang
No Relationships to Disclose
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Jianzhen Shan
No Relationships to Disclose
 
Rujiao Liu
No Relationships to Disclose
 
Robin Guo
Research Funding - AstraZeneca (Inst); Merck (Inst); Prelude Therapeutics (Inst)
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Zhen Liu
No Relationships to Disclose
 
Shuiping Gao
No Relationships to Disclose
 
Xiaohua Wu
No Relationships to Disclose
 
Alexander Starodub
No Relationships to Disclose
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Nashat Gabrail
Consulting or Advisory Role - Celgene; Chemiocare
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Janssen Oncology; Karyopharm Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tesaro/GSK
Research Funding - Amgen (Inst); Bayer (Inst); Chemiocare (Inst); Chemiocare (Inst); Kartos Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Oncology Supply
 
Satish Shah
No Relationships to Disclose
 
Yiwei Chen
Employment - Lepu Biopharma
 
Dan Liu
Employment - Lepu Biopharma
 
Chen Cheng
Employment - Lepu Biopharma
 
Xianjun Yu
No Relationships to Disclose